drugset
drugset / Trial / NCT03703466

A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

NCT03703466 ↗

Phase 2 Completed 72 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to examine the side effects that participants with metastatic breast cancer experience when taking abemaciclib with or without food.

Timeline

Start
2018-11-28
Primary completion
2019-07-29
Completion
2023-03-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Abemaciclib Small molecule 200 mg Oral

Indications

breast cancer